EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

Kazuomi Kario iD, Tomohiro Katsuya, Tatsuo Shimosawa, Takashi Taguchi, Ayumi Tanabe, Mitsuru Ohishi, ESCORT‐HT investigators

The Journal of Clinical Hypertension · 2025

DOI: 10.1111/jch.14947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Kazuomi Kario und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan. Hauptthemen laut MEDLINE: Angiotensin Receptor Antagonists, Antihypertensive Agents, Calcium Channel Blockers, Hypertension. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed as first‐ and second‐line treatments for older Japanese patients with hypertension. However, due to age‐related decline in renin activity, the effectiveness of ARBs may decrease. This highlights the need for other antihypertensive agents to be used in combination with CCBs to replace ARBs for more effective blood pressure (BP) control. The ESCORT‐HT study is a multicenter, randomized, controlled, open‐label, parallel‐group study with a 4‐week run‐in period and 12‐week treatment period. This study aims to evaluate the efficacy of esaxerenone as a second‐line treatment for hypertension and to determine whether its BP‐lowering effect is noninferior to that of ARBs in older patients with uncontrolled hypertension on CCB monotherapy. The safety profiles of esaxerenone and ARBs will also be evaluated. Patients will be randomly assigned in a 1:1 ratio to receive either esaxerenone or an ARB. The primary efficacy endpoint will be the change from baseline in morning home systolic BP at the end of the treatment period. The BP‐lowering effect of esaxerenone will be considered noninferior to that of ARBs if the upper limit of the two‐sided 95% confidence interval (CI) for the difference in systolic BP change between esaxerenone and ARB is

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersHypertensionAgedAged, 80 and overFemaleHumansMaleMiddle AgedBlood PressureDrug Therapy, CombinationJapanTreatment OutcomeEquivalence Trials as TopicMulticenter Studies as TopicPyrrolesSulfones

Stichwörter der Autor:innen

angiotensin II receptor blockersesaxerenonehypertensionmineralocorticoid receptor blockersrandomized comparative study

Substanzen

Angiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersesaxerenonePyrrolesSulfones

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
  • Katsuya Clinic, Amagasaki, Hyogo, Japan.
  • Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
  • Primary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, Japan.
  • Data Intelligence Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.
  • Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima, Japan.

ORCID-Profile: Kazuomi Kario

Förderung

  • Daiichi Sankyo Co., Ltd.

Zitieren

APA

Kario, K., Katsuya, T., Shimosawa, T., Taguchi, T., Tanabe, A., Ohishi, M., & ESCORT‐HT investigators (2025). Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT). The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14947

Vancouver

Kario K, Katsuya T, Shimosawa T, Taguchi T, Tanabe A, Ohishi M, et al. Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT). The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.14947

BibTeX
@article{Kario2025,
  author = {Kario, Kazuomi and Katsuya, Tomohiro and Shimosawa, Tatsuo and Taguchi, Takashi and Tanabe, Ayumi and Ohishi, Mitsuru and ESCORT‐HT investigators, ESCORT‐HT investigators},
  title = {Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)},
  journal = {The Journal of Clinical Hypertension},
  year = {2025},
  doi = {10.1111/jch.14947}
}
Kostenlos starten →